Evidence map›Paper›PMID 34636300›Full record

ArticleCurrent neuropharmacology2022

Perspective on mTOR-dependent Protection in Status Epilepticus.

Francesca Biagioni, Roberta Celli, Filippo Sean Giorgi, Ferdinando Nicoletti, Francesco Fornai

Open access · greenAbstract read
In one paragraph

Article in Current neuropharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 50% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Francesca BiagioniI.R.C.C.S. Neuromed, Pozzilli, Italy.
Roberta CelliI.R.C.C.S. Neuromed, Pozzilli, Italy.
Filippo Sean GiorgiHuman Anatomy, Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy.
Ferdinando NicolettiI.R.C.C.S. Neuromed, Pozzilli, Italy.
Francesco FornaiI.R.C.C.S. Neuromed, Pozzilli, Italy.
Istituto Neurologico Mediterraneo · ITUniversity of Pisa · ITSapienza University of Rome · IT

Funding

Cinque per Mille to IRCCS Neuromed 874/2020-PR
6 · The paper itself

Abstract

backgroundThe piriform cortex, known as area tempestas, has a high propensity to trigger limbic epileptic seizures. Recent studies on human patients indicate that a resection containing the piriform cortex produces a marked improvement in patients suffering from intractable limbic seizures. This calls for looking back at the pharmacological and anatomical data on area tempestas. Within the piriform cortex, status epilepticus can be induced by impairing the desensitization of AMPA receptors. The mechanistic target of rapamycin complex1 (mTORC1) is a promising candidate.

objectiveThe present perspective aims to link the novel role of the piriform cortex with recent evidence on the modulation of AMPA receptors under the influence of mTORC1. This is based on recent evidence and preliminary data, leading to the formulation of interaction between mTORC1 and AMPA receptors to mitigate the onset of long-lasting, self-sustaining, neurotoxic status epilepticus.

methodsThe perspective grounds its method on recent literature along with the actual experimental procedure to elicit status epilepticus from the piriform cortex and the method to administer the mTORC1 inhibitor rapamycin to mitigate seizure expression and brain damage.

resultsThe available and present perspectives converge to show that rapamycin may disrupt the seizure circuitry initiated in the piriform cortex to mitigate seizure duration, severity, and brain damage.

conclusionThe perspective provides a novel scenario to understand refractory epilepsy and selfsustaining status epilepticus. It is expected to provide a beneficial outcome in patients suffering from temporal lobe epilepsy.

Indexed as

Receptors, AMPAStatus EpilepticusHumansMechanistic Target of Rapamycin Complex 1SeizuresSirolimusTOR Serine-Threonine KinasesMechanistic Target of Rapamycin Complex 1MTOR protein, humanReceptors, AMPASirolimusTOR Serine-Threonine Kinasesarea tempestasautophagymTORpiriform cortexrapamycinStatus epilepticus

Identifiers

PMID34636300
PMCPMC9886823
OpenAlexW3207831062

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.